recursion pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics. our platform has resulted in the massive parallelization of drug discovery. we have deployed this platform in pursuit of drugs for the treatment of rare genetic diseases. we partner or out-license these leads to major pharmaceutical companies early in development. our horizontal business model focused on discovery accelerates our impact and reduces our costs by avoiding slow and costly in-house development, and allows us to spread risk across many new therapeutic opportunities.
Company profile
Ticker
RXRX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Recursion Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Recursion Pharmaceuticals Canada, Inc. • Valence Discovery Inc. • Valence Discovery USA, Inc. • Cyclica Therapeutics Inc. • Cyclica Ltd. • Cyclica Inc. • Giro Health Inc. • 1414517 B.C. Unlimited Liability Company • CereXis, Inc. ...
IRS number
464099738
RXRX stock data
Latest filings (excl ownership)
8-K
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Its Download Day
24 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 24
DEFA14A
Additional proxy soliciting materials
24 May 24
8-K
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
24 May 24
S-8
Registration of securities for employees
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
Latest ownership filings
4
Michael Secora
17 Jun 24
144/A
Notice of proposed sale of securities (amended)
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
4
Blake Borgeson
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
4
Christopher Gibson
7 Jun 24
144
Notice of proposed sale of securities
6 Jun 24
4
Terry-Ann Burrell
5 Jun 24
4
ROBERT HERSHBERG
5 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 306.15 mm | 306.15 mm | 306.15 mm | 306.15 mm | 306.15 mm | 306.15 mm |
Cash burn (monthly) | 31.76 mm | 14.69 mm | 32.11 mm | 31.38 mm | 34.10 mm | 26.40 mm |
Cash used (since last report) | 89.36 mm | 41.32 mm | 90.36 mm | 88.29 mm | 95.95 mm | 74.28 mm |
Cash remaining | 216.79 mm | 264.83 mm | 215.79 mm | 217.86 mm | 210.20 mm | 231.87 mm |
Runway (months of cash) | 6.8 | 18.0 | 6.7 | 6.9 | 6.2 | 8.8 |
Institutional ownership, Q1 2024
95.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 238 |
Opened positions | 110 |
Closed positions | 22 |
Increased positions | 54 |
Reduced positions | 41 |
13F shares | Current |
---|---|
Total value | 2.06 tn |
Total shares | 220.32 mm |
Total puts | 1.52 mm |
Total calls | 786.60 k |
Total put/call ratio | 1.9 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 24.59 mm | $245.14 bn |
Baillie Gifford & Co | 24.07 mm | $239.96 bn |
Vanguard | 16.01 mm | $159.67 bn |
Mubadala Investment Co PJSC | 12.99 mm | $129.47 bn |
BLK Blackrock | 12.32 mm | $122.84 bn |
Kinnevik AB (publ) | 10.41 mm | $103.74 bn |
CMTDF Sumitomo Mitsui Trust | 10.36 mm | $103.32 bn |
Nikko Asset Management Americas | 10.36 mm | $103.11 bn |
STT State Street | 10.35 mm | $103.21 bn |
FMR | 9.26 mm | $92.33 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Jun 24 | Michael Secora | Class A Common Stock | Sell | Dispose S | No | Yes | 9.2721 | 15,000 | 139.08 k | 1,267,843 |
14 Jun 24 | Michael Secora | Class A Common Stock | Option exercise | Acquire M | No | Yes | 2.22 | 39,375 | 87.41 k | 1,282,843 |
14 Jun 24 | Michael Secora | Stock Option Class A Common Stock | Option exercise | Dispose M | No | Yes | 2.22 | 39,375 | 87.41 k | 731,385 |
13 Jun 24 | Michael Secora | Class A Common Stock | Sell | Dispose S | No | Yes | 9.3199 | 15,000 | 139.80 k | 1,243,468 |
13 Jun 24 | Michael Secora | Class A Common Stock | Option exercise | Acquire M | No | Yes | 2.22 | 39,375 | 87.41 k | 1,258,468 |
13 Jun 24 | Michael Secora | Stock Option Class A Common Stock | Option exercise | Dispose M | No | Yes | 2.22 | 39,375 | 87.41 k | 770,760 |
11 Jun 24 | Blake Borgeson | Class A Common Stock | Sell | Dispose S | No | Yes | 8.4531 | 11,447 | 96.76 k | 7,188,563 |
6 Jun 24 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | No | Yes | 9 | 50,000 | 450.00 k | 708,738 |
5 Jun 24 | Christopher Gibson | Class A Common Stock | Sell | Dispose S | No | Yes | 8.42 | 50,000 | 421.00 k | 758,738 |
5 Jun 24 | Christopher Gibson | Class A Common Stock | Gift | Dispose G | No | Yes | 0 | 25,000 | 0.00 | 808,738 |
News
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
18 Jun 24
How Is The Market Feeling About Recursion Pharmaceuticals?
30 May 24
Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
23 May 24
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
14 May 24
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
13 May 24
Press releases
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
29 May 24
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
24 May 24
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
13 May 24
Recursion to Participate in Upcoming Investor Conferences
1 May 24
AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029
25 Apr 24